Nurix Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €228.86M +108.3% -€189.36M -34.0% -82.7% +1.8 pp N/A N/A
    (estimated) €109.85M +86.3% -€286.84M -7.0% -261.1% +2.6 pp N/A N/A
    (estimated) €58.96M +12.3% -€308.44M +9.0% -523.1% +0.16 pp -€263.08M +17.9% -446.2% -0.21 pp
    (estimated) €52.52M -27.9% -€283.02M +26.5% -538.9% -2.3 pp -€223.12M +54.7% -424.9% -2.3 pp
    (estimated) €72.81M +56.5% -€223.78M +35.5% -307.4% +0.47 pp -€144.19M +3.5% -198.0% +1.0 pp
    €46.53M -29.1% -€165.10M +34.5% -354.9% -1.7 pp -€139.30M +123.8% -299.4% -2.0 pp
    €65.67M +99.3% -€122.78M -13.3% -187.0% +2.4 pp -€62.23M -50.6% -94.8% +2.9 pp
    €32.95M +29.8% -€141.63M +41.7% -429.9% -0.36 pp -€125.86M +87.5% -382.0% -1.2 pp
    €25.38M +66.9% -€99.96M +171.0% -393.9% -1.5 pp -€67.13M -1,859.5% -264.6% -2.9 pp
    €15.20M -42.7% -€36.88M +99.3% -242.7% -1.7 pp €3.82M +98.6% 25.1% +0.18 pp
    €26.54M -16.9% -€18.51M +130.2% -69.7% -0.45 pp €1.92M -107.5% 7.2% +0.88 pp
    €31.94M -€8.04M -25.2% -€25.66M -80.3%

    Notifications